| Literature DB >> 20663127 |
Kenzo Uchida1, Hideaki Nakajima, Takayuki Hirai, Takafumi Yayama, Ke-Bing Chen, Shigeru Kobayashi, Sally Roberts, William E Johnson, Hisatoshi Baba.
Abstract
BACKGROUND: The application of mechanical insults to the spinal cord results in profound cellular and molecular changes, including the induction of neuronal cell death and altered gene expression profiles. Previous studies have described alterations in gene expression following spinal cord injury, but the specificity of this response to mechanical stimuli is difficult to investigate in vivo. Therefore, we have investigated the effect of cyclic tensile stresses on cultured spinal cord cells from E15 Sprague-Dawley rats, using the FX3000 Flexercell Strain Unit. We examined cell morphology and viability over a 72 hour time course. Microarray analysis of gene expression was performed using the Affymetrix GeneChip System, where categorization of identified genes was performed using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) systems. Changes in expression of 12 genes were validated with quantitative real-time reverse transcription polymerase chain reaction (RT-PCR).Entities:
Mesh:
Year: 2010 PMID: 20663127 PMCID: PMC2912916 DOI: 10.1186/1471-2202-11-84
Source DB: PubMed Journal: BMC Neurosci ISSN: 1471-2202 Impact factor: 3.288
Figure 1The application of cyclic tensile stress induced apoptotic cell death in spinal cord cells. Representative serial photomicrographs are shown of cells exposed to a tensile stress of 10% strain at 0.5 Hz at 0, 6, 24, and 48 hours (A, B). The number of green-stained living cells decreased (A: top row) while the number of red-strained dead cells increased (B: middle row) in a time-dependent manner during cyclic tensile stress application. Transmission electron microscopy (TEM) examination (C: bottom row) showed that all cells at 0 hour appeared viable, with large nuclei, and dotted with chromatin and abundant rough endoplasmic reticulum, while some cells at 6 hours showed deformity of nuclei and cytoplasm. TEM at 24 hours showed some cells with condensed and fragmented nuclei and condensed chromatin, and the change progressed at 48 hours (C: bottom row). Bar = 100 μm (A, B), 50 μm (C).
Figure 2The survival rate of spinal cord cells was dependent on the level, frequency and duration of the applied tensile strain. The survival rate (%) of living cells during the application of a standardized cyclic tensile stress (10%, 0.5 Hz) compared with stress-free baseline (A). Gray bar: stress-free condition; white bar: cyclic tensile stress condition. The survival rate (%) of living cells after 6 hours at three different strain levels of 5%, 10%, and 15% and two different strain frequencies of 0.5 Hz and 1 Hz compared with that at the standardized strain level of 10% at 0.5 Hz frequency (B). Data are expressed as mean ± SEM of 6 experiments. *P < 0.05, **P < 0.01.
Figure 3Gene expression profiles in spinal cord cells after the application of cyclic tensile stress. The hierarchial clustering data are presented graphically as a heatmap (A). These genes were subsequently grouped into six subclusters (cluster 1-6) according to the time course of gene expression pattern (B).
List of "apoptosis" genes selectively upregulated in cluster 3
| Gene Symbol | Gene Name | 2 hr | 6 hr | 12 hr | 24 hr | 48 hr | 72 hr | |
|---|---|---|---|---|---|---|---|---|
| Nr4a2 | nuclear receptor subfamily 4, group A, member 2 | 54278 | 1.60 | 1.30 | ||||
| Fosl1 | fos-like antigen 1 | 25445 | 1.69 | |||||
| Itgav | integrin alpha V | 296456 | 1.39 | 1.56 | ||||
| Twist2 | twist homolog 2 (Drosophila) | 59327 | 1.42 | 1.50 | 1.37 | 1.58 | ||
| Rarb | retinoic acid receptor, beta | 24706 | 0.89 | 0.83 | 1.42 | 1.80 | ||
| Dusp1 | dual specificity phosphatase 1 | 114856 | 0.96 | 1.70 | 1.89 | 1.47 | ||
| Hmox1 | heme oxygenase (decycling) 1 | 24451 | 1.63 | |||||
| Angptl4 | angiopoietin-like 4 | 362850 | 1.23 | 1.28 | 1.33 | 1.98 | ||
| Acin1 | apoptotic chromatin condensation inducer 1 | 305884 | 0.92 | 0.67 | 1.31 | |||
| Pdgfrb | Platelet derived growth factor receptor, beta polypeptide | 24629 | 0.84 | 0.77 | 1.71 | 1.92 | ||
| Gclc | glutamate-cysteine ligase, catalytic subunit | 25283 | 1.25 | 1.99 | 1.58 | 1.80 | ||
| Ihpk2 | inositol hexaphosphate kinase 2 | 59268 | 1.07 | 1.17 | 1.26 | 1.64 | ||
| Dapk1 | death associated protein kinase 1 | 306722 | 0.85 | 0.95 | 1.55 | 1.38 | ||
| Amigo2 | adhesion molecule with Ig like domain 2 | 300186 | 0.87 | 0.93 | 1.00 | 1.33 | 1.49 | |
| Mmp2 | matrix metallopeptidase 2 | 81686 | 1.05 | 1.12 | 1.32 | 1.48 | 1.92 | |
| Hipk2 | Homeodomain interacting protein kinase 2 | 362342 | 1.01 | 1.63 | 2.14 | 1.86 | ||
| Birc3 | baculoviral IAP repeat-containing 3 | 78971 | 1.52 | 1.63 | 1.22 | 1.48 | ||
| Myd116 | myeloid differentiation primary response gene 116 | 171071 | 1.09 | 1.90 | 2.17 | 1.58 | ||
| Il1rn | interleukin 1 receptor antagonist | 60582 | 1.73 | 1.77 | ||||
| Hipk1 | homeodomain interacting protein kinase 1 | 365895 | 1.12 | 1.05 | 1.30 | 1.37 | ||
| LOC687118 | similar to death effector domain-containing DNA binding protein 2 | 687118 | 1.58 | 1.58 | ||||
| Ripk2 | receptor (TNFRSF)-interacting serine-threonine kinase 2 | 362491 | 1.04 | 1.33 | 1.48 | 1.69 | ||
| Dapk1 | death associated protein kinase 1 | 306722 | 0.97 | 1.00 | 1.16 | 1.35 | ||
| Timp3 | Tissue inhibitor of metalloproteinase 3 | 25358 | 1.16 | 1.08 | 1.28 | 1.01 | 1.78 | |
| Cln3 | ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease) | 293485 | 1.17 | 1.56 | 1.50 | |||
| Ercc5 | excision repair cross-complementing rodent repair deficiency, complementation group 5 | 301382 | 1.05 | 1.29 | 1.30 | |||
| Pik3ca | phosphatidylinositol 3-kinase, catalytic, alpha polypeptide | 170911 | 1.08 | 1.05 | 1.45 | 1.63 | ||
| Raf1 | v-raf-leukemia viral oncogene 1 | 24703 | 1.13 | 1.66 | 1.71 | 1.73 | ||
| Ednrb | endothelin receptor type B | 50672 | 1.32 | 1.09 | 1.46 | 1.94 | 1.31 | |
| Cd24 | CD24 molecule | 25145 | 0.78 | 0.61 | 0.70 | 0.71 | 1.39 | |
| Hipk2 | homeodomain interacting protein kinase 2 | 362342 | 0.93 | 0.99 | 1.47 | 1.35 | ||
| Timp3 | Tissue inhibitor of metalloproteinase 3 | 25358 | 1.10 | 0.85 | 1.13 | 0.98 | 1.36 | |
| Vegfa | vascular endothelial growth factor A | 83785 | 0.89 | 1.20 | 0.94 | 1.09 | ||
| Gal | galanin | 29141 | 1.32 | 1.22 | 1.85 | 0.77 | 1.84 | |
| Furin | furin (paired basic amino acid cleaving enzyme) | 54281 | 1.17 | 1.20 | 1.36 | 1.18 | 1.89 | |
| Ep300 | E1A binding protein p300 | 170915 | 1.33 | 1.09 | 1.23 | 1.29 | ||
| Sh3kbp1 | SH3-domain kinase binding protein 1 | 84357 | 1.03 | 1.58 | 1.78 | 1.47 | 1.85 | |
| Psen2 | presenilin 2 | 81751 | 1.37 | 1.52 | 1.91 | 1.81 | ||
| Ptk2b | PTK2 protein tyrosine kinase 2 beta | 50646 | 0.93 | 1.29 | 1.95 | 1.69 | 1.81 | |
| LOC687813 | similar to Tnf receptor-associated factor 1 | 687813 | 1.87 | 1.68 | 1.75 | |||
| Ncf1 | neutrophil cytosolic factor 1 | 114553 | 1.83 | 1.75 | ||||
| Apbb2 | amyloid beta (A4) precursor protein-binding, family B, member 2 | 305338 | 1.09 | 1.12 | 1.48 | 1.28 | 1.74 | |
| Cln8 | ceroid-lipofuscinosis, neuronal 8 | 306619 | 1.52 | 1.77 | 1.94 | 1.73 | ||
| Sh3kbp1 | SH3-domain kinase binding protein 1 | 84357 | 1.15 | 1.41 | 1.47 | 1.58 | 1.72 |
List of "response to stimulus" genes selectively upregulated in cluster 1
| Gene Symbol | Gene Name | 2 hr | 6 hr | 12 hr | 24 hr | 48 hr | 72 hr | |
|---|---|---|---|---|---|---|---|---|
| Serpina3n | serine (or cysteine) peptidase inhibitor, clade A, member 3N | 24795 | 1.53 | |||||
| Ereg | epiregulin | 59325 | 1.99 | |||||
| Ptgs2 | prostaglandin-endoperoxide synthase 2 | 29527 | 1.55 | |||||
| Ccl20 | chemokine (C-C motif) ligand 20 | 29538 | 1.20 | 1.83 | ||||
| Cxcl3 | chemokine (C-X-C motif) ligand 3 | 171551 | 1.62 | |||||
| Hspa4l | heat shock protein 4 like | 294993 | 0.80 | 0.62 | 1.19 | |||
| Grem1 | gremlin 1 | 50566 | 1.11 | 1.45 | 1.12 | |||
| Nupr1 | nuclear protein 1 | 113900 | 0.93 | 0.81 | 1.69 | 1.34 | ||
| Cryab | crystallin, alpha B | 25420 | 0.83 | 0.88 | 1.35 | 1.06 | ||
| Gls | glutaminase | 24398 | 1.00 | 1.15 | 1.89 | 1.73 | ||
| Cyp4b1 | cytochrome P450, family 4, subfamily b, polypeptide 1 | 24307 | 0.72 | 1.75 | 1.26 | 0.66 | 1.42 | |
| Sncg | synuclein, gamma | 64347 | 0.95 | 0.77 | 0.92 | 1.12 | ||
| Vnn1 | vanin 1 | 29142 | 1.10 | 1.37 | 1.43 | 1.31 | 1.64 | |
| Gls | glutaminase | 24398 | 0.88 | 0.94 | 0.79 | 0.92 | 1.66 | |
| Cxcl10 | chemokine (C-X-C motif) ligand 10 | 245920 | 1.23 | 1.01 | 0.84 | 1.08 | 1.65 | |
| Inhbb | Inhibin beta-B | 25196 | 0.97 | 1.01 | 1.14 | 1.32 | 0.97 | |
| Slc12a2 | solute carrier family 12 (sodium/potassium/chloride transporters), member 2 | 83629 | 0.88 | 0.88 | 0.97 | 0.88 | 1.58 |
High frequency pathways* identified by KEGG/pathway analysis in clusters 1, 2, and 3
| rank | pathway (total gene count) | p-value | count |
|---|---|---|---|
| cluster 1 | |||
| 1 | Glutamate metabolism (26) | 0.0021 | 2 |
| 2 | D-Glutamine and D-glutamate metabolism (3) | 0.0081 | 1 |
| 3 | Taurine and hypotaurine metabolism (10) | 0.0266 | 1 |
| 4 | Pantothenate and CoA biosynthesis (11) | 0.0293 | 1 |
| cluster 2 | |||
| 1 | T cell receptor signaling pathway (95) | 0.0156 | 2 |
| 2 | Glycosphingolipid biosynthesis - ganglio series (15) | 0.0307 | 1 |
| 3 | Cell adhesion molecules (CAMs) (151) | 0.0371 | 2 |
| cluster 3 | |||
| 1 | Focal adhesion (187) | 0.0001 | 17 |
| 2 | Bladder cancer (36) | 0.0001 | 7 |
| 3 | TGF-beta signaling pathway (81) | 0.0003 | 10 |
| 4 | Pathways in cancer (313) | 0.0005 | 22 |
| 5 | Prostate cancer (92) | 0.0008 | 10 |
| 6 | Small cell lung cancer (92) | 0.0008 | 10 |
| 7 | ECM-receptor interaction (74) | 0.0028 | 8 |
| 8 | Glioma (64) | 0.0047 | 7 |
| 9 | Melanoma (69) | 0.0072 | 7 |
| 10 | Renal cell carcinoma (69) | 0.0072 | 7 |
| 11 | PPAR signaling pathway (70) | 0.0078 | 7 |
| 12 | mTOR signaling pathway (54) | 0.0081 | 6 |
| 13 | Gap junction (90) | 0.0091 | 8 |
| 14 | Glycerophospholipid metabolism (46) | 0.0168 | 5 |
| 15 | MAPK signaling pathway (255) | 0.0200 | 15 |
| 16 | Non-small cell lung cancer (52) | 0.0273 | 5 |
| 17 | Pancreatic cancer (71) | 0.0286 | 6 |
| 18 | GnRH signaling pathway (91) | 0.0296 | 7 |
| 19 | Adherens junction (73) | 0.0323 | 6 |
| 20 | Pyruvate metabolism (38) | 0.0351 | 4 |
| 21 | Regulation of actin cytoskeleton (204) | 0.0357 | 12 |
| 22 | Leukocyte transendothelial migration (116) | 0.0366 | 8 |
| 23 | Chronic myeloid leukemia (79) | 0.0449 | 6 |
| 24 | Glutathione metabolism (42) | 0.0482 | 4 |
*, Listed pathways are all statistically significant (P < 0.05). "total gene count" means the number of genes in each pathway, which have already been registered in KEGG system, and "count" means the number of genes, which were expressed significantly in each pathway in this study.
Figure 4The effects of cyclic tensile stress on gene expression levels analyzed by real time RT-PCR. Application of cyclic tensile stress resulted in significant increases in mRNA expression levels of platelet derived growth factor receptor (PDGFR), guanine nucleotide binding protein gamma 12 (G12) at 12 hours, neurotrophic tyrosine kinase receptor type 2 (trkA/B), fibroblast growth factor receptor (FGFR), mitogen-activated protein kinase kinase kinase kinase 4 (HGK) at 24 hours, and calcium channel voltage-dependent L type alpha 1F subunit (CACN), v-raf-leukemia viral oncogene 1 (Raf1), dual specificity phosphatase 1 (MKP), mitogen-activated protein kinase 8 interacting protein 3 (JIP3), heat shock protein 72 (HSP72), DNA-damage-inducible alpha (GAD D45), DNA-damage inducible transcript 3 (GAD D153) at 48-72 hours. Red bars indicate significant differences (P < 0.05) in upregulation at least 2-fold in comparison to controls. Data are mean ± SEM of 3 experiments.
Sequences of primers used for real-time PCR
| Target Protein | Forward Primer | Reverse Primer | PCR Product Size (bp) | |
|---|---|---|---|---|
| CACN | 5'-TCACCATTGCCTCCGAACACTA-3' | 5'-CAGGAGCATTTCTGCCGTGA-3' | 104 | NM012517 |
| TrkA/B | 5'-GCCACACAATGTTGCCCATC-3' | 5'-AAGGACTCTGCCCTGGGTGA-3' | 185 | NM012731 |
| FGFR | 5'-TTGCCGAATGAAGACCACGA-3' | 5'-GGAGTTCATGGACGAGCTGGA-3' | 130 | NM001109892 |
| PDGFR | 5'-GAATGACCACGGCGATGAGA-3' | 5'-GGATAAGCCTCAAACACCACCTG-3' | 141 | NM031525 |
| G12 | 5'-CAAGATGCTGGTGGCTGTCAA-3' | 5'-AGCAGCTCTGCCTCACGATG-3' | 81 | NM021589 |
| Raf1 | 5'- AACAGTGAAGTCGCGCTGGA-3' | 5'- CAGCACAATGCCATAGGAGTAGACA-3' | 145 | NM012639 |
| MKP | 5'-ACAACCACAAGGCAGACATTAGCTC-3' | 5'- CAGATGGTGGCTGACCTGGA-3' | 127 | NM053769 |
| JIP3 | 5'-AGCCTGCCTGCCAAGTACAAG-3' | 5'-TCAGGTTGACACCAGCAGCAC-3' | 148 | NM001100673 |
| HGK | 5'-TTCACCATGTCATTCACCGAGA-3' | 5'-CCAGCTGAGCGCTTACACCA-3' | 99 | NM001106904 |
| HSP72 | 5'-GCTTTCACCTCAAGCCTTTGGA-3' | 5'-CGGGCCTCATGCACACATAG-3' | 117 | NM212504 |
| GAD D45 | 5'-AGGCAGCCAAGCTGCTCAA-3' | 5'-ACGTCCCGGTCGTCATCTTC-3' | 82 | NM024127 |
| GAD D153 | 5'-TGGAAGCCTGGTATGAGGATCTG-3' | 5'-GAGGTGCTTGTGACCTCTGCTG-3' | 175 | NM024134 |
| GAPDH | 5'-GGCACAGTCAAGGCTGAGAATG-3' | 5'-ATGGTGGTGAAGACGCCAGTA-3' | 143 | NM017008 |